Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
CA Cancer J Clin ; 66(4): 271-89, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-27253694

RESUMO

The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population. For the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results cancer registries. In addition, current treatment patterns for the most prevalent cancer types are presented based on information in the National Cancer Data Base and treatment-related side effects are briefly described. More than 15.5 million Americans with a history of cancer were alive on January 1, 2016, and this number is projected to reach more than 20 million by January 1, 2026. The 3 most prevalent cancers are prostate (3,306,760), colon and rectum (724,690), and melanoma (614,460) among males and breast (3,560,570), uterine corpus (757,190), and colon and rectum (727,350) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost one-half (47%) are aged 70 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by primary care providers. Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care. CA Cancer J Clin 2016;66:271-289. © 2016 American Cancer Society.


Assuntos
Neoplasias/mortalidade , Neoplasias/terapia , Sobreviventes/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , American Cancer Society , Neoplasias da Mama/mortalidade , Neoplasias da Mama/terapia , Criança , Pré-Escolar , Neoplasias do Colo/mortalidade , Neoplasias do Colo/terapia , Medicina Baseada em Evidências , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Melanoma/mortalidade , Melanoma/terapia , Pessoa de Meia-Idade , National Cancer Institute (U.S.) , Neoplasias/diagnóstico , Neoplasias/epidemiologia , Prevalência , Neoplasias da Próstata/mortalidade , Neoplasias da Próstata/terapia , Sistema de Registros , Fatores de Risco , Neoplasias Cutâneas/mortalidade , Neoplasias Cutâneas/terapia , Taxa de Sobrevida , Estados Unidos/epidemiologia , Neoplasias Uterinas/mortalidade , Neoplasias Uterinas/terapia
2.
CA Cancer J Clin ; 64(4): 252-71, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24890451

RESUMO

The number of cancer survivors continues to increase due to the aging and growth of the population and improvements in early detection and treatment. In order for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborated to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results (SEER) program registries. In addition, current treatment patterns for the most common cancer types are described based on information in the National Cancer Data Base and the SEER and SEER-Medicare linked databases; treatment-related side effects are also briefly described. Nearly 14.5 million Americans with a history of cancer were alive on January 1, 2014; by January 1, 2024, that number will increase to nearly 19 million. The 3 most common prevalent cancers among males are prostate cancer (43%), colorectal cancer (9%), and melanoma (8%), and those among females are cancers of the breast (41%), uterine corpus (8%), and colon and rectum (8%). The age distribution of survivors varies substantially by cancer type. For example, the majority of prostate cancer survivors (62%) are aged 70 years or older, whereas less than one-third (32%) of melanoma survivors are in this older age group. It is important for clinicians to understand the unique medical and psychosocial needs of cancer survivors and to proactively assess and manage these issues. There are a growing number of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship.


Assuntos
Neoplasias/epidemiologia , Neoplasias/terapia , Sobreviventes/estatística & dados numéricos , Feminino , Humanos , Incidência , Masculino , Estadiamento de Neoplasias , Neoplasias/patologia , Prevalência , Programa de SEER , Estados Unidos/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA